Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBIT: 2022-2024

Historic EBIT for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to -$3.1 million.

  • Addex Therapeutics' EBIT rose 10.98% to -$885,260 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.8 million, marking a year-over-year increase of 21.92%. This contributed to the annual value of -$3.1 million for FY2024, which is 25.40% down from last year.
  • Per Addex Therapeutics' latest filing, its EBIT stood at -$3.1 million for FY2024, which was down 25.40% from -$2.5 million recorded in FY2023.
  • Addex Therapeutics' EBIT's 5-year high stood at -$2.5 million during FY2023, with a 5-year trough of -$11.0 million in FY2022.
  • In the last 3 years, Addex Therapeutics' EBIT had a median value of -$3.1 million in 2024 and averaged -$5.6 million.
  • As far as peak fluctuations go, Addex Therapeutics' EBIT soared by 77.40% in 2023, and later dropped by 25.40% in 2024.
  • Over the past 3 years, Addex Therapeutics' EBIT (Yearly) stood at -$11.0 million in 2022, then surged by 77.40% to -$2.5 million in 2023, then dropped by 25.40% to -$3.1 million in 2024.